{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:38:37Z","timestamp":1757453917481,"version":"3.41.0"},"reference-count":63,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443344831"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.podrm.2024.10.002","type":"book-chapter","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T12:40:09Z","timestamp":1736426409000},"page":"43-96","source":"Crossref","is-referenced-by-count":1,"title":["Nateglinide: A comprehensive profile"],"prefix":"10.1016","author":[{"given":"Manal M.","family":"Alanazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/bs.podrm.2024.10.002_bib1","unstructured":"H. Favre, W. Powell, Nomenclature of Organic Chemistry: IUPAC Recommendations and Preferred Names, Royal Society of Chemistry, 2013, ISBN 978-0-85404-182-4."},{"key":"10.1016\/bs.podrm.2024.10.002_bib2","series-title":"Pharmaceuticals, Body Fluids and Postmortem Material","first-page":"1759","article-title":"Clarke\u2019s analysis of drugs and poisons","author":"Moffat","year":"2011"},{"key":"10.1016\/bs.podrm.2024.10.002_bib3","unstructured":"The name THE MERCK INDEX Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., The Royal Society of Chemistry for use in the U.S.A. and Canada. [cited 2023 9\/4]; from https:\/\/merckindex.rsc.org\/search-results?q=Nateglinide."},{"key":"10.1016\/bs.podrm.2024.10.002_bib4","first-page":"1","article-title":"Determination of electronics and molecular structure of nateglinine anti-diabetic drug using DFT","volume":"1","author":"Suleiman","year":"2019","journal-title":"J. Theor. Appl. Phys."},{"key":"10.1016\/bs.podrm.2024.10.002_bib5","unstructured":"Nateglinide tablets for oral use. [prescribing information] Cambridge ARIAD Pharmaceuticals, Inc 2023. Highlights of prescribing information; from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/077467s000lbl.pdf, 2024."},{"key":"10.1016\/bs.podrm.2024.10.002_bib6","unstructured":"Nateglinide, Product information; from https:\/\/cdn.caymanchem.com\/cdn\/insert\/2332, 2024."},{"key":"10.1016\/bs.podrm.2024.10.002_bib7","unstructured":"(n.d.) \u3008https:\/\/www.chemicalbook.com\/ProductMSDSDetailCB9472923_EN.htm\u3009."},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.002_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.diabres.2005.08.004","article-title":"Beneficial effects of Nateglinide on insulin resistance in type 2 diabetes","volume":"71","author":"Hazama","year":"2006","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/bs.podrm.2024.10.002_bib9","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s10973-015-4714-x","article-title":"Improving water solubility of Nateglinide by complexation of b-cyclodextrin","volume":"123","author":"Ikeda","year":"2016","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/bs.podrm.2024.10.002_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jsps.2011.06.005","article-title":"Stability-indicating HPTLC method for simultaneous determination of Nateglinide and metformin hydrochloride in pharmaceutical dosage form","volume":"19","author":"Thomas","year":"2011","journal-title":"Saudi Pharm. J."},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.002_bib11","article-title":"Development and validation of stress induced stability indicating UV-spectroscopic method for nateglinide bulk and pharmaceutical formulations","volume":"3","author":"Chaudhari","year":"2013","journal-title":"Am. J. PharmTech Res."},{"issue":"5","key":"10.1016\/bs.podrm.2024.10.002_bib12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/00304940409356630","article-title":"An efficient large scale synthesis of Nateglinide","volume":"36","author":"Chandrasekhar","year":"2004","journal-title":"Org. Prep. Proced. Int."},{"issue":"17","key":"10.1016\/bs.podrm.2024.10.002_bib13","doi-asserted-by":"crossref","first-page":"7883","DOI":"10.1021\/jm300997w","article-title":"Synthesis and biological investigations of nitric oxide releasing Nateglinide and meglitinide type II antidiabetic prodrugs: in-vivo antihyperglycemic activities and blood pressure lowering studies","volume":"55","author":"Kaur","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.podrm.2024.10.002_bib14","unstructured":"R.N. Kankan, D.R. Rao, M. singh, D.R. Birari, Process for the preparation of Nateglinide. Int. search. Rep., WO2005121071A1, n.d."},{"issue":"5","key":"10.1016\/bs.podrm.2024.10.002_bib15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/03639040601134140","article-title":"A validated stability indicating LC method for Nateglinide","volume":"33","author":"Pathare","year":"2007","journal-title":"Drug. Dev. Ind. Pharm."},{"year":"2024","key":"10.1016\/bs.podrm.2024.10.002_bib16"},{"key":"10.1016\/bs.podrm.2024.10.002_bib17","unstructured":"Japanese pharmacopoeia, Nateglinide, 18 (n.d.) 1406\u20131408."},{"issue":"6","key":"10.1016\/bs.podrm.2024.10.002_bib18","first-page":"1","article-title":"Forced degradation studies of nateglinide by the first-order derivative spectrophotometric method and the density functional theory of the Nateglinide molecule","author":"Karasakal","year":"2022","journal-title":"J. Appl. Spectrosc."},{"key":"10.1016\/bs.podrm.2024.10.002_bib19","unstructured":"P. Kumari, et al., Identification and characterization of degradation products of Nateglinide, n.d."},{"key":"10.1016\/bs.podrm.2024.10.002_bib20","unstructured":"G. Frenkel, B. Gome, S. Wizel, Crystalline form of Nateglinide. Int. Search. Rep., WO2004067496A1, n.d."},{"issue":"10","key":"10.1016\/bs.podrm.2024.10.002_bib21","first-page":"119","article-title":"Exploring structural aspects of nateglinide polymorphs using powder X-ray diffraction","volume":"9","author":"Goyal","year":"2017","journal-title":"Int. J."},{"issue":"5","key":"10.1016\/bs.podrm.2024.10.002_bib22","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jpba.2010.12.003","article-title":"Determination of the Nateglinide polymorphic purity through DSC","volume":"54","author":"Bruni","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.podrm.2024.10.002_bib23","article-title":"FT-IR, Laser-Raman, UV-Vis, and NMR spectroscopic studies of antidiabetic molecule Nateglinide","author":"Ozdemir","year":"2018","journal-title":"J. Spectrosc."},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.002_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1515\/chem-2016-0023","article-title":"Analytical tools for determination of new oral antidiabetic drugs, glitazones, gliptins, gliflozins and glinides, in bulk materials, pharmaceuticals and biological samples","volume":"14","author":"Gumieniczek","year":"2016","journal-title":"Open. Chem."},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.002_bib25","first-page":"497","article-title":"Spectrophotometric determination of Nateglinide using 2, 4-dinitrophenyl hydrazine and potassium ferricyanide in pharmaceutical dosage form","volume":"3","author":"Sireesha","year":"2011","journal-title":"Der Pharma Chemica"},{"key":"10.1016\/bs.podrm.2024.10.002_bib26","unstructured":"P.S. Teja, B. Aruna, Vis-spectrophotometric methods for the determination of Nateglinide, n.d."},{"key":"10.1016\/bs.podrm.2024.10.002_bib27","first-page":"803","article-title":"Quantitative estimation of Nateglinide in pharmaceutical dosage forms by visible spectrophotometry","volume":"3","author":"Babu","year":"2013","journal-title":"Int. J. Res. Pharm. Chem."},{"key":"10.1016\/bs.podrm.2024.10.002_bib28","article-title":"Spectrophotometric determination of Nateglinide","author":"Rajasekaran","year":"2004","journal-title":"Indian. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/bs.podrm.2024.10.002_bib29","first-page":"36","article-title":"Development and validation of bathochromically shifted UV spectrophotometric area under curve method for quantitative estimation of nateglinide in API and tablet dosage form","volume":"5","author":"N. M","year":"2016","journal-title":"World J. Pharm. Res."},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.002_bib30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5958\/2231-5675.2020.00024.1","article-title":"Development of UV-spectrophotometric method for the simultaneous estimation of Nateglinide and piperine in combined tablet dosage form","volume":"10","author":"Venkatesh","year":"2020","journal-title":"Asian J. Pharm. Anal."},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.002_bib31","first-page":"102","article-title":"Estimation of Nateglinide and metformin hydrochloride in tablet dosage form by spectrophotometric methods","volume":"10","author":"Thomas","year":"2011","journal-title":"J. Pharm. Res."},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.002_bib32","first-page":"271","article-title":"Simultaneous spectrophotometric estimations of Nateglinide and Metformin hydrochloride in pharmaceutical formulation","volume":"3","author":"Thomas","year":"2011","journal-title":"Der Pharma Chemica"},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.002_bib33","first-page":"153","article-title":"UV-spectrophotometric determination of nateglinide in bulk and pharmaceutical dosage form using hydrotropic solubilization technique","volume":"8","author":"Gowripattapu","year":"2016","journal-title":"Int. J. Pharm. Sci. Drug. Res."},{"key":"10.1016\/bs.podrm.2024.10.002_bib34","unstructured":"N. O. Ozcelik, Sevgi Tatar Ulu, and Serap Saglik Aslan. Spectrofluorimetric Determination of Nateglinide in Pharmaceutical Preparations, n.d."},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.002_bib35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.7868\/S0030403414010024","article-title":"Spectrofluorimetric determination of Nateglinide in pure and pharmaceutical preparations through derivatization with 4-chloro-7-nitrobenzo-2-oxa-1, 3-diazole","volume":"116","author":"Karasakal","year":"2014","journal-title":"\u041e\u043f\u0442\u0438\u043a\u0430 \u0438 \u0441\u043f\u0435\u043a\u0442\u0440\u043e\u0441\u043a\u043e\u043f\u0438\u044f"},{"issue":"11","key":"10.1016\/bs.podrm.2024.10.002_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/jms.4789","article-title":"Design of experiment-based LC-MS\/MS method development for simultaneous estimation of Nateglinide and metformin hydrochloride in rat plasma","volume":"56","author":"Patel","year":"2021","journal-title":"J. Mass. Spectrom."},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.002_bib37","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0731-7085(02)00680-5","article-title":"Rapid and simple method for the analysis of Nateglinide in human plasma using HPLC analysis with UV detection","volume":"31","author":"Bauer","year":"2003","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"2","key":"10.1016\/bs.podrm.2024.10.002_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.12991\/mpj.2015199640","article-title":"Development and validation of an HPLC method for determination of Nateglinide in drug substances","volume":"19","author":"Hacio\u011flu","year":"2015","journal-title":"Marmara Pharm. J."},{"issue":"4","key":"10.1016\/bs.podrm.2024.10.002_bib39","first-page":"267","article-title":"Development and validation of rp-hplc method for metformin hydrochloride and Nateglinide in bulk and combined dosage form","volume":"8","author":"Chengalva","year":"2016","journal-title":"Int. J. Pharm. Pharm Sci."},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.002_bib40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.22159\/ajpcr.2021.v14i1.39530","article-title":"Validation of a developed analytical method for determination of nateglinide and metformin Hcl in pure and pharmaceutical dosage form by reversed-phase high-performance liquid chromatography and its degradation studies","volume":"14","author":"ISMAIL","year":"2021","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"10.1016\/bs.podrm.2024.10.002_bib41","first-page":"37","article-title":"Method development and validation of nateglinide and gliclazide by using RP-HPLC","volume":"10","author":"Paisa","year":"2021","journal-title":"Int. J. Pharm. Biol. Sci."},{"issue":"7-8","key":"10.1016\/bs.podrm.2024.10.002_bib42","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1365\/s10337-008-0548-z","article-title":"Development of a new analytical method for determination of related components in Nateglinide","volume":"67","author":"Madhavi","year":"2008","journal-title":"Chromatographia"},{"issue":"12","key":"10.1016\/bs.podrm.2024.10.002_bib43","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s12272-010-1218-x","article-title":"Determination of the L-enantiomer of Nateglinide in pharmaceutical formulations by micellar electrokinetic chromatography","volume":"33","author":"Phan","year":"2010","journal-title":"Arch. Pharm. Res."},{"issue":"3","key":"10.1016\/bs.podrm.2024.10.002_bib44","first-page":"326","article-title":"Simultaneous determination of the Cis-Isomer and L-Isomer in Nateglinide by HPLC","volume":"54","author":"Dong Shubo","year":"2018","journal-title":"Phys. Test. Chem. Anal. Part. B: Chem. Anal."},{"issue":"4","key":"10.1016\/bs.podrm.2024.10.002_bib45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/chromsci\/bmz116","article-title":"Simultaneous pharmacokinetics estimation of nateglinide and pioglitazone by RP-HPLC: computational study to unlock the synergism","volume":"58","author":"Dey","year":"2020","journal-title":"J. Chromatogr. Sci."},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.002_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s43094-023-00503-2","article-title":"A stability indicating UPLC method development and validation for the simultaneous estimation of Nateglinide and metformin hydrochloride in bulk and tablet dosage form","volume":"9","author":"Narikimalli","year":"2023","journal-title":"Futur. J. Pharm. Sci."},{"issue":"17","key":"10.1016\/bs.podrm.2024.10.002_bib47","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1080\/00032710802424230","article-title":"Simultaneous chiral separation of geometry isomers and enantiomers of Nateglinide by capillary electrophoresis with mixture of CD derivations as chiral selector","volume":"41","author":"Bao-hui","year":"2008","journal-title":"Anal. Lett."},{"issue":"1","key":"10.1016\/bs.podrm.2024.10.002_bib48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jpba.2004.05.001","article-title":"Determination of Nateglinide in animal plasma by micellar electrokinetic chromatography and on-line sweeping technique","volume":"36","author":"Yan","year":"2004","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"7","key":"10.1016\/bs.podrm.2024.10.002_bib49","first-page":"860","article-title":"Study of protein binding of acidic drug, Nateglinide, in human plasma albumin solution by high performance capillary electrophoresis\/frontal analysis","volume":"31","author":"Zhao","year":"2003","journal-title":"Chin. J. Anal. Chem."},{"key":"10.1016\/bs.podrm.2024.10.002_bib50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.talanta.2015.09.008","article-title":"Preparation of polyclonal antibodies for Nateglinide (NTG) and development of a sensitive chemiluminescent immunoassay to detect NTG in tablets and serum","volume":"146","author":"Zheng","year":"2016","journal-title":"Talanta"},{"key":"10.1016\/bs.podrm.2024.10.002_bib51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00125-002-0935-1","article-title":"The mechanisms underlying the unique pharmacodynamics of Nateglinide","volume":"46","author":"Hu","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/bs.podrm.2024.10.002_bib52","series-title":"Martindale the Complete Drug Refernces","first-page":"431","author":"Sweetman","year":"2009"},{"key":"10.1016\/bs.podrm.2024.10.002_bib53","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bbamem.2004.12.005","article-title":"Intestinal uptake of Nateglinide by an intestinal fluorescein transporter","volume":"1668","author":"Itagaki","year":"2005","journal-title":"Biochimica et. Biophysica Acta"},{"key":"10.1016\/bs.podrm.2024.10.002_bib54","series-title":"Pharmacology and Therapeutics for Dentistry","first-page":"437","author":"Dowd","year":"2017"},{"issue":"4","key":"10.1016\/bs.podrm.2024.10.002_bib55","first-page":"415","article-title":"Pharmacokinetics and metabolism of Nateglinide in humans","volume":"29","author":"Weaver","year":"2001","journal-title":"Drug. Metab. Disposition"},{"issue":"2","key":"10.1016\/bs.podrm.2024.10.002_bib56","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2165\/00003088-200443020-00003","article-title":"Clinical pharmacokinetics of Nateglinide","volume":"43","author":"McLeod","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/bs.podrm.2024.10.002_bib57","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0091270002239825","article-title":"Pharmacokinetics of Nateglinide in renally impaired diabetic patients","volume":"43","author":"Devineni","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/bs.podrm.2024.10.002_bib58","first-page":"634","article-title":"Single-dose pharmacokinetics of Nateglinide in subjects with hepatic cirrhosis","volume":"40","author":"Choudhury","year":"2000","journal-title":"J. Clin. Pharmacol."},{"issue":"8\u20139","key":"10.1016\/bs.podrm.2024.10.002_bib59","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/bdd.724","article-title":"Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of Nateglinide in rabbits","volume":"31","author":"Kim","year":"2010","journal-title":"Biopharm. Drug. Dispos."},{"issue":"6","key":"10.1016\/bs.podrm.2024.10.002_bib60","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2133\/dmpk.22.409","article-title":"Prediction of the metabolic interaction of Nateglinide with other drugs based on in vitro studies","volume":"22","author":"Takanohashi","year":"2007","journal-title":"Drug. Metab. Pharmacokinet."},{"issue":"2","key":"10.1016\/bs.podrm.2024.10.002_bib61","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-200746020-00001","article-title":"Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and Nateglinide","volume":"46","author":"Scheen","year":"2007","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/bs.podrm.2024.10.002_bib62","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF00542449","article-title":"Effect of rifampicin on the pharmacokinetics and pharmacodynamics of Nateglinide in healthy subjects","volume":"56","author":"Niemi","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/bs.podrm.2024.10.002_bib63","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/00912709922007606","article-title":"The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects","volume":"39","author":"Karara","year":"1999","journal-title":"J. Clin. Pharmacol."}],"container-title":["Profiles of Drug Substances, Excipients and Related Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512524000189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512524000189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T11:56:48Z","timestamp":1750852608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871512524000189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443344831"],"references-count":63,"URL":"https:\/\/doi.org\/10.1016\/bs.podrm.2024.10.002","relation":{},"ISSN":["1871-5125"],"issn-type":[{"type":"print","value":"1871-5125"}],"subject":[],"published":{"date-parts":[[2025]]}}}